Clinical features and treatment challenges of HER2-positive primary breast squamous cell carcinoma: a case report and literature review

• by Fang Yang, Siyu Guo, Ping Li, Mengqi Yang, Xuan Wu

• July 9, 2026

FDA Approves Daraxonrasib for Metastatic Pancreatic Cancer Following Landmark Clinical Trial Led by Dana-Farber

he U.S. Food and Drug Administration (FDA) has approved daraxonrasib, an oral multi-selective RAS(ON) inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.

• by

• August 26, 2026

• 5 min

Implementation Strategies in Cascade Genetic Testing—The Devil Is in the Details

• by Kari L. Ring

• August 27, 2026

Cognitive Behavior vs Bright Light Therapy for Insomnia in Women Undergoing Chemotherapy for Breast Cancer: A

• by Trang Thuy Do, Jordan Maccora, Rebecca Wallace, Veronica Aedo-Lopez, Marliese Alexander, Sonia Ancoli-Israel, Bei Bei, Robert Blum, Frances Boyle, Daphne Day, Justine Diggens, Prudence A. Francis, Maria Ftanou, Sheila N. Garland, Alysia Kepert, Duncan Mortimer, Andrew J. K. Phillips, Sharad Sharma, Lesley Stafford, Michelle White, Joshua F. Wiley

• August 27, 2026